RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchas...
June 18 2021 - 12:24PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in oncology and inflammatory
diseases, today announced the closing of its previously announced
underwritten public offering of 4,356,060 shares of its common
stock at a price to the public of $33.00 per share, which
includes 568,181 shares issued and sold upon full exercise of the
underwriters’ option to purchase additional shares of common stock.
All of the shares of common stock were offered by RAPT. The
aggregate gross proceeds to RAPT from the offering were
approximately $143.7 million, before deducting underwriting
discounts and commissions and other offering expenses.
J.P. Morgan, SVB Leerink and Piper Sandler acted as joint lead
book-running managers for the offering. Cantor acted as
book-running manager for the offering. H.C. Wainwright & Co.
and Roth Capital Partners acted as co-lead managers for the
offering.
The offering was made pursuant to a shelf registration
statement, including a base prospectus, filed by RAPT with
the Securities and Exchange Commission (SEC), which was
declared effective by the SEC on November 16, 2020. The offering
was made only by means of a prospectus supplement and accompanying
prospectus. The final prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC’s website at www.sec.gov.
Alternatively, electronic copies of the final prospectus supplement
and the accompanying prospectus may also be obtained from: J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by email at
prospectus-eq_fi@jpmorgan.com or by telephone at (866) 803-9204;
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by email at
syndicate@svbleerink.com or by telephone at (800) 808-7525, ext.
6105; or Piper Sandler & Co., 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, Attention: Prospectus Department, by email
at prospectus@psc.com or by telephone at (800) 747-3924.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based
biopharmaceutical company focused on discovering, developing and
commercializing oral small molecule therapies for patients with
significant unmet needs in oncology and inflammatory diseases.
Utilizing its proprietary discovery and development engine, the
Company is developing highly selective small molecules designed to
modulate the critical immune drivers underlying these diseases.
RAPT has discovered and advanced two unique drug candidates, FLX475
and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4),
for the treatment of cancer and inflammation, respectively. The
Company is also pursuing a range of targets that are in the
discovery stage of development.
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024